A Phase 3 interventional study of Etoricoxib and Ibuprofen in Dysmenorrhea, sponsored by Organon and Co. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a study to determine the overall analgesic effect of a single oral dose of etoricoxib compared to ibuprofen in participants with moderate-to-severe primary dysmenorrhea.
Participants who meet all the study entry criteria will be randomly allocated to 2 possible sequences of the 2 treatment regimens over the course of 2 menstrual cycles.
In treatment sequence 1, participants will receive etoricoxib 120 mg daily in menstrual cycle 1, and ibuprofen up to 2400 mg/daily in menstrual cycle 2. In treatment sequence 2, participants will receive ibuprofen up to 2400 mg/daily in menstrual cycle 1 and etoricoxib 120 mg daily in menstrual cycle 2.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
This study's enrollment of 139 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Browse Dysmenorrhea studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
Drug: Etoricoxib · Drug: Ibuprofen · Drug: Placebo to etoricoxib · Drug: Placebo to ibuprofen · Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
Drug: Etoricoxib · Drug: Ibuprofen · Drug: Placebo to etoricoxib · Drug: Placebo to ibuprofen · Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
Etoricoxib 120 mg tablet given orally for one dose.
Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
Placebo to etoricoxib, one tablet.
Placebo to ibuprofen, up to four 3-capsule doses.
Drug page: Acetaminophen
Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
Also known as: Saridon
Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose
TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24, with increasing scores indicating greater pain relief.
Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours
Sum of Pain Intensity Difference Scores Over the 6-Hour Time Period (SPID6)
The Pain Intensity Difference (PID) score is the difference between the baseline pain intensity (PI) score and the PI score recorded at each time point post initial dose, as calculated by subtracting the pain intensity at each of the subsequent time points from the baseline pain intensity score; therefore, it is on a -1 to 3 scale, with a large value representing a greater treatment effect. SPID6 is derived by multiplying the PID score at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours and it is on a scale of -6 to 18.
Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours
Mean Participant Global Evaluation of Pain at 6 Hours After the Initial Dose (GLOBAL6)
The GLOBAL6 was recorded by the participant at 6 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL6 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.
Time frame: 6 hours
Mean Participant Global Evaluation of Pain at 24 Hours After the Initial Dose (GLOBAL24)
The GLOBAL24 was recorded by the participant at 24 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL24 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.
Time frame: 24 hours
Mean Time to >=1 Unit Improvement From Baseline in Pain Intensity During the 6 Hours After the Initial Dose
The time to a change from baseline in pain intensity score of \>=1 unit on the pain intensity scale was calculated. The pain intensity scale rates participant pain on a scale of -1 to 3, with larger values associated with greater treatment effect.
Time frame: Baseline and 6 hours
Peak Pain Intensity Difference (PID) During the 6 Hours After the Initial Dose
Peak PID during the 6 hours post initial dose is defined as the maximum PID score recorded during first 6 hours after the initial dose of study medication. PID is evaluated on a scale of -1 to 3, with larger values representing a greater treatment effect.
Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours
Peak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose
Peak PR during the 6 hours post initial dose is defined as the maximum PR score recorded during the first 6 hours after the initial dose of study medication. PR is recorded on a scale of 0 to 4, with 0 = no pain relief, 1 = little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.
Time frame: Up to 6 hours
Number of Participants Using Rescue Medication 24 Hours After the Initial Dose
Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg (Saridon) was provided to each participant as rescue medication. Participants were permitted to take 2 tablets at a time and up to 3 doses within 24 hours of dosing of study drug for rescue purposes.
Time frame: 24 Hours
PID at Up to 12 Hours Following the Initial Dose
PID during the 12 hours following the initial dose is defined as the maximum PID score recorded during first 12 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.
Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 and 12 hours
PR at Up to 12 Hours Following the Initial Dose
PR during the 12 hours following the initial dose is defined as the maximum PR score recorded during the first 12 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.
Time frame: Up to 12 hours
PID at Up to 24 Hours Following the Initial Dose
PID during the 24 hours following the initial dose is defined as the maximum PID score recorded during first 24 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.
Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 20 and 24 hours
PR at Up to 24 Hours Following the Initial Dose
PR during the 24 hours following the initial dose is defined as the maximum PR score recorded during the first 24 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.
Time frame: Up to 24 hours
Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 6 Hours After the Initial Dose
At 6 hours following the initial dose. participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 6 hours post initial dose were summed.
Time frame: 6 hours
Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose
At 24 hours following the initial dose of study medication, participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 24 hours post initial dose were summed.
Time frame: 24 Hours
| Milestone | Etoricoxib 120 mg/ Ibuprofen Up to 2400 mg | Ibuprofen Up to 2400 mg / Etoricoxib 120 mg |
|---|---|---|
| Started | 69 | 70 |
| Completed | 68 | 65 |
| Not completed | 1 | 5 |
| Withdrew: Lack of qualifying event | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 |
TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24, with increasing scores indicating greater pain relief.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose | 17.38 ± 0.37 | 16.49 ± 0.37 |
The Pain Intensity Difference (PID) score is the difference between the baseline pain intensity (PI) score and the PI score recorded at each time point post initial dose, as calculated by subtracting the pain intensity at each of the subsequent time points from the baseline pain intensity score; therefore, it is on a -1 to 3 scale, with a large value representing a greater treatment effect. SPID6 is derived by multiplying the PID score at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours and it is on a scale of -6 to 18.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Sum of Pain Intensity Difference Scores Over the 6-Hour Time Period (SPID6) | 9.48 ± 0.58 | 9.27 ± 0.58 |
The GLOBAL6 was recorded by the participant at 6 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL6 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Mean Participant Global Evaluation of Pain at 6 Hours After the Initial Dose (GLOBAL6) | 2.50 ± 0.08 | 2.24 ± 0.08 |
The GLOBAL24 was recorded by the participant at 24 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL24 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Mean Participant Global Evaluation of Pain at 24 Hours After the Initial Dose (GLOBAL24) | 2.65 ± 0.08 | 2.29 ± 0.08 |
The time to a change from baseline in pain intensity score of \>=1 unit on the pain intensity scale was calculated. The pain intensity scale rates participant pain on a scale of -1 to 3, with larger values associated with greater treatment effect.
| Hours | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Mean Time to >=1 Unit Improvement From Baseline in Pain Intensity During the 6 Hours After the Initial Dose | 1.0 (1.0 to 1.5) | 1.5 (1.0 to 1.5) |
Peak PID during the 6 hours post initial dose is defined as the maximum PID score recorded during first 6 hours after the initial dose of study medication. PID is evaluated on a scale of -1 to 3, with larger values representing a greater treatment effect.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Peak Pain Intensity Difference (PID) During the 6 Hours After the Initial Dose | 2.2 ± 0.4 | 2.1 ± 0.4 |
Peak PR during the 6 hours post initial dose is defined as the maximum PR score recorded during the first 6 hours after the initial dose of study medication. PR is recorded on a scale of 0 to 4, with 0 = no pain relief, 1 = little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Peak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose | 3.70 ± 0.06 | 3.52 ± 0.06 |
Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg (Saridon) was provided to each participant as rescue medication. Participants were permitted to take 2 tablets at a time and up to 3 doses within 24 hours of dosing of study drug for rescue purposes.
| Participants | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Number of Participants Using Rescue Medication 24 Hours After the Initial Dose | 1 | 4 |
PID during the 12 hours following the initial dose is defined as the maximum PID score recorded during first 12 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| PID at Up to 12 Hours Following the Initial Dose | 2.28 ± 0.04 | 2.07 ± 0.04 |
PR during the 12 hours following the initial dose is defined as the maximum PR score recorded during the first 12 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| PR at Up to 12 Hours Following the Initial Dose | 3.73 ± 0.07 | 3.45 ± 0.07 |
PID during the 24 hours following the initial dose is defined as the maximum PID score recorded during first 24 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| PID at Up to 24 Hours Following the Initial Dose | 2.36 ± 0.04 | 2.25 ± 0.04 |
PR during the 24 hours following the initial dose is defined as the maximum PR score recorded during the first 24 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.
| Score on a Scale | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| PR at Up to 24 Hours Following the Initial Dose | 3.88 ± 0.07 | 3.62 ± 0.07 |
At 6 hours following the initial dose. participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 6 hours post initial dose were summed.
| Participants | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 6 Hours After the Initial Dose | 111 | 103 |
At 24 hours following the initial dose of study medication, participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 24 hours post initial dose were summed.
| Participants | Etoricoxib 120 mg | Ibuprofen up to 2400 mg |
|---|---|---|
| Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose | 113 | 101 |
Collected over From the time of the initial (first) dose of study medication up to 14 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etoricoxib 120 mg / Ibuprofen up to 2400 mg/Daily | — | 0/69 (0%) | 0/69 (0%) |
| Ibuprofen up to 2400 mg / Etoricoxib 120 mg | — | 0/70 (0%) | 0/70 (0%) |
| Age, Customized(Participants) | All Randomized Participants |
|---|---|
| <=20 years | 14 |
| 21-29 years | 118 |
| >=30 years | 7 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 139 |
| Male | 0 |
No study locations are listed for this record.
The record gives a start of Nov 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etoricoxib · Ibuprofen